文献速递基础与转化研究新药、器械与细胞基因治疗研发组学、生物样本库与精准医学

高保真PAMless碱基编辑造血干细胞治疗慢性肉芽肿病

High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease.
PubMed 文献 · Sci Transl Med · 2024-10-16

X-linked chronic granulomatous disease (X-CGD) is an inborn error of immunity (IEI) resulting from genetic mutations in the cytochrome b-245 beta chain (CYBB) gene.…

要点

  • 对碱基编辑后HSPC的脱靶DNA编辑、转录组RNA编辑及染色体扰动分析显示脱靶或旁观编辑极少。
  • 编辑等位基因在移植入免疫缺陷小鼠后持续存在,支持首次人体临床试验(NCT06325709)。

核心结论

  • PAMless碱基编辑器ABE8e-SpRY可高效、精确纠正X-CGD突变,支持开展首次人体临床试验(NCT06325709),并为治疗其他先天性免疫缺陷突变提供潜在蓝图。

研究设计与样本

  • 研究使用腺嘌呤碱基编辑器ABE8e-SpRY在人造血干祖细胞(HSPC)中纠正X-CGD致病突变,并评估脱靶DNA编辑、转录组RNA编辑及染色体扰动,同时将碱基编辑后HSPC移植入免疫缺陷小鼠观察编辑等位基因持久性。

主要发现

  • 对碱基编辑后HSPC的脱靶DNA编辑、转录组RNA编辑及染色体扰动分析显示脱靶或旁观编辑极少。
  • 碱基编辑后HSPC移植入免疫缺陷小鼠后,编辑等位基因持续存在。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

X-linked chronic granulomatous disease (X-CGD) is an inborn error of immunity (IEI) resulting from genetic mutations in the cytochrome b-245 beta chain (CYBB) gene. The applicability of base editors (BEs) to correct mutations that cause X-CGD is constrained by the requirement of Cas enzymes to recognize specific protospacer adjacent motifs (PAMs). Our recently engineered PAMless Cas enzyme, SpRY, can overcome the PAM limitation. However, the efficiency, specificity, and applicability of SpRY-based BEs to correct mutations in human hematopoietic stem and progenitor cells (HSPCs) have not been thoroughly examined. Here, we demonstrated that the adenine BE ABE8e-SpRY can access a range of target sites in HSPCs to correct mutations causative of X-CGD. For the prototypical X-CGD mutation CYBB c.676C>T, ABE8e-SpRY achieved up to 70% correction, reaching efficiencies greater than three-and-one-half times higher than previous CRISPR nuclease and donor template approaches. We profiled potential off-target DNA edits, transcriptome-wide RNA edits, and chromosomal perturbations in base-edited HSPCs, which together revealed minimal off-target or bystander edits. Edited alleles persisted after transplantation of the base-edited HSPCs into immunodeficient mice. Together, these investigational new drug-enabling studies demonstrated efficient and precise correction of an X-CGD mutation with PAMless BEs, supporting a first-in-human clinical trial (NCT06325709) and providing a potential blueprint for treatment of other IEI mutations.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Bzhilyanskaya V, Ma L, Liu S, et al. High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease. Sci Transl Med. 2024. PMID: 39413163. doi:10.1126/scitranslmed.adj6779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。